Critical Outcome’s cancer drug continues positive track record

Critical Outcome Technologies (TSX-V:COT) has obtained positive results from new animal studies with its COTI-2 oral drug candidate, demonstrating efficacy as a single agent and in combination with first line therapies, and with low toxicity, in animal models of human cancers. In a statement, the company said COTI-2, as a single agent, demonstrated efficacy comparable [...]

Critical Outcome MOA on COTI-2

Critical Outcome Technologies (TSX-V:COT) for the first time has outlined the specific cellular target and mechanism of action for its lead oncology candidate COTI-2. “We have now demonstrated through a series of key experiments that the Pleckstrin Homology domain of (the protein) AKT/AKT2 is a selective cellular target for COTI-2,” Critical Outcome president Dr. Wayne [...]